The University of Chicago Header Logo

Connection

Ravi Salgia to Biomarkers, Tumor

Back to Details
This is a "connection" page, showing publications Ravi Salgia has written about Biomarkers, Tumor.
Ravi Salgia
Connection Strength
4.901
Biomarkers, Tumor
  1. MET receptor in oncology: From biomarker to therapeutic target. Adv Cancer Res. 2020; 147:259-301.
    View in: PubMed
    Score: 0.420
  2. Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma. Am J Clin Oncol. 2019 04; 42(4):337-344.
    View in: PubMed
    Score: 0.386
  3. EphB4: A promising target for upper aerodigestive malignancies. Biochim Biophys Acta Rev Cancer. 2018 Apr; 1869(2):128-137.
    View in: PubMed
    Score: 0.356
  4. MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. Mol Cancer Ther. 2017 04; 16(4):555-565.
    View in: PubMed
    Score: 0.336
  5. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study. Invest New Drugs. 2017 06; 35(3):334-344.
    View in: PubMed
    Score: 0.335
  6. Molecular biomarkers for future screening of lung cancer. J Surg Oncol. 2013 Oct; 108(5):327-33.
    View in: PubMed
    Score: 0.260
  7. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res. 2013 Jan 01; 73(1):184-94.
    View in: PubMed
    Score: 0.247
  8. Differential expression of RON in small and non-small cell lung cancers. Genes Chromosomes Cancer. 2012 Sep; 51(9):841-51.
    View in: PubMed
    Score: 0.240
  9. Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer. 2011 Sep 01; 117(17):3889-99.
    View in: PubMed
    Score: 0.220
  10. MET and phosphorylated MET as potential biomarkers in lung cancer. J Environ Pathol Toxicol Oncol. 2011; 30(4):341-54.
    View in: PubMed
    Score: 0.218
  11. Biomarker discovery in lung cancer--promises and challenges of clinical proteomics. Mass Spectrom Rev. 2007 May-Jun; 26(3):451-66.
    View in: PubMed
    Score: 0.169
  12. Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res. 2004 Mar-Apr; 24(2C):1031-8.
    View in: PubMed
    Score: 0.136
  13. Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. Anticancer Res. 2003 Jan-Feb; 23(1A):49-62.
    View in: PubMed
    Score: 0.125
  14. Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma. Clin Lung Cancer. 2022 03; 23(2):e137-e139.
    View in: PubMed
    Score: 0.113
  15. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. Chest. 2021 09; 160(3):1095-1107.
    View in: PubMed
    Score: 0.111
  16. RNA-based therapies: A cog in the wheel of lung cancer defense. Mol Cancer. 2021 03 19; 20(1):54.
    View in: PubMed
    Score: 0.111
  17. Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors. Clin Colorectal Cancer. 2021 06; 20(2):e129-e138.
    View in: PubMed
    Score: 0.109
  18. Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. Lung Cancer. 2020 08; 146:174-181.
    View in: PubMed
    Score: 0.104
  19. Therapeutic targeting of miRNA-216b in cancer. Cancer Lett. 2020 08 01; 484:16-28.
    View in: PubMed
    Score: 0.104
  20. Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. Future Oncol. 2020 Jan; 16(1):4289-4301.
    View in: PubMed
    Score: 0.101
  21. Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. J Thorac Oncol. 2019 10; 14(10):1704-1717.
    View in: PubMed
    Score: 0.098
  22. Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy. BMC Cancer. 2018 03 21; 18(1):314.
    View in: PubMed
    Score: 0.090
  23. Value-Based Medicine and Integration of Tumor Biology. Am Soc Clin Oncol Educ Book. 2017; 37:833-840.
    View in: PubMed
    Score: 0.083
  24. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget. 2016 Oct 11; 7(41):66880-66891.
    View in: PubMed
    Score: 0.081
  25. FAK and paxillin, two potential targets in pancreatic cancer. Oncotarget. 2016 May 24; 7(21):31586-601.
    View in: PubMed
    Score: 0.079
  26. MET as a possible target for non-small-cell lung cancer. J Clin Oncol. 2013 Mar 10; 31(8):1089-96.
    View in: PubMed
    Score: 0.063
  27. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov. 2011 Dec; 1(7):573-9.
    View in: PubMed
    Score: 0.058
  28. Case 1: small bowel obstruction due to metastatic lung cancer. J Clin Oncol. 2000 Jan; 18(1):227-8.
    View in: PubMed
    Score: 0.025
  29. Cancer-associated retinopathy in a patient with non-small-cell lung carcinoma. Lung Cancer. 1998 Nov; 22(2):149-52.
    View in: PubMed
    Score: 0.023
  30. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317.
    View in: PubMed
    Score: 0.023
  31. Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience. Oncotarget. 2017 Jun 27; 8(26):42198-42213.
    View in: PubMed
    Score: 0.021
  32. Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer. Oncotarget. 2016 Mar 22; 7(12):13621-33.
    View in: PubMed
    Score: 0.020
  33. Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer. 2013 Jul; 81(1):138-41.
    View in: PubMed
    Score: 0.016
  34. Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol Biomarkers Prev. 2008 May; 17(5):1104-10.
    View in: PubMed
    Score: 0.011
  35. Detection and analysis of lung cancer cells from body fluids using a rare event imaging system. Methods Mol Med. 2003; 75:423-30.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.